DB-107

N/A

Report date: 2024/09/06 10:12:07

Base Information

Drug NameDB-107
Drug Alias NameVocimagene amiretrorepvec + 5-fluorocytosineFlucytosine prodrug activating therapy - TocagenVocimagene amiretrorepvec + flucytosineToca-511 + Toca-FCToca 511 + 5-FC +[11] 
ClassificationCell and gene therapy > Gene therapy > Viral vector-based gene therapy > Retroviral vector
Mechanisms of ActionCytosine deaminase modulatorsGene transference
TargetsCytosine deaminase
Therapy Area/IndicationsSolid tumoursUrinary Bladder NeoplasmsCarcinoma, Non-Small-Cell Lung +[16] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaUnited StatesTaiwan +[8] 
CombinationsYes Flucytosine
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesTocagen Inc
China Registration ClassN/A

Develop Information

Active CompaniesApolloBio CorpDenovo Biopharma Llc
Inactive CompaniesTocagen IncNational Cancer Institute
Active IndicationsGangliogliomaAstrocytomaGlioma
Inactive IndicationsSolid tumoursUrinary Bladder NeoplasmsCarcinoma, Non-Small-Cell Lung +[13] 

Other Information

ATC CodeN/A
Related LinksN/A